Windlas Biotech earnings calls.
Other · 2 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹233 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
0
Across 1 tracked commitments: 0 delivered, 1 missed.
Call date
Pending
latest available source date
Signal trajectory
2 actual quartersCurrent read
0/100
Across 1 tracked commitments: 0 delivered, 1 missed.
Latest source read
What changed this quarter?
Windlas Biotech reported its 10th consecutive quarter of record revenue with 20% YoY revenue growth to ₹210 crore in Q1 FY26, outpacing the Indian pharma market's 9% growth. EBITDA rose 27% to ₹27 crore with margins expanding 70bps to 12.6%, driven by gross margin improvement of 71bps to 38.3%. PAT grew 31% to ₹18 crore with EPS of ₹8.4 (+30% YoY). All three verticals delivered healthy growth: CDMO (₹160 crore, +17.8%), Trade Generics (₹44 crore, +25.2%), and Exports (₹6 crore, +45.4%). The injectable facility is ramping up with improving utilization quarter-on-quarter, while Plant 6 refurbishment remains on track for phase-wise commercialization by late FY26 with ₹40-50 crore capex budgeted. Peak revenue potential is ₹1,100 crore (₹1,000 crore oral solids + ₹100 crore injectables) upon full capacity utilization. Risk: Injectable facility ramp-up remains slow; trade generics showed sequential softness; management declined to provide quantitative guidance or injectable utilization details.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹233 Cr
Source date
Pending
Across the record
Quarter history.
History modules